Alkem Lab

Who are the top shareholders of the Alkem Lab?

The top shareholders of Alkem Lab include promoters, with Sarandhar Singh holding 19.42%, mutual funds at 14.97%, foreign institutional investors at 9.41%, and individual investors with a combined 15.77%. The largest public shareholder is the ICICI Prudential Multi-Asset Fund, holding 4.11%.

The top shareholders of Alkem Lab include a mix of promoters, mutual funds, and foreign institutional investors (FIIs). The majority shareholders are the promoters, with Sarandhar Singh holding the highest individual stake at 19.42%. Mutual funds collectively hold 14.97% of the shares through 27 different schemes, while FIIs account for 9.41% with 473 different investors. The highest public shareholder is the ICICI Prudential Multi-Asset Fund, which holds 4.11%. Additionally, individual investors have a combined holding of 15.77%.

how big is Alkem Lab?

As of Jun 06, Alkem Laboratories Ltd has a market capitalization of 58,204.24 Cr, with recent net sales of 12,756.59 Cr and net profit of 2,153.18 Cr over the last four quarters.

Market Cap: Alkem Laboratories Ltd has a market capitalization of 58,204.24 Cr and is classified as a Large Cap company as of Jun 06.<BR><BR>Recent Quarterly Performance: The sum of Net Sales for the latest 4 quarters, which includes Dec'24, Sep'24, Jun'24, and Mar'24, is 12,756.59 Cr. The sum of Net Profit for the same period is 2,153.18 Cr. This data is on a Consolidated basis.<BR><BR>Balance Sheet Snapshot: This is Consolidated data for the latest annual period ending in Mar'24. The Shareholder's Funds are reported at 10,312.06 Cr, while the Total Assets amount to 14,060.07 Cr.

Has Alkem Lab declared dividend?

Yes, Alkem Laboratories Ltd has declared a dividend of 1850% (₹37 per share), with an ex-date of February 14, 2025. The company has shown varying total returns over different periods, with a notable 110.91% total return over the last 5 years.

Alkem Laboratories Ltd has declared a dividend.<BR><BR>Dividend Details:<BR>- Percentage announced: 1850%<BR>- Amount per share: 37<BR>- Ex-date: 14 Feb 25<BR><BR>Dividend Yield: 0.87%.<BR><BR>Total Returns by Period:<BR>Over the last 6 months, the price return was -11.76%, the dividend return was 0.67%, resulting in a total return of -11.09%.<BR><BR>In the 1-year period, the price return was 1.02%, the dividend return was 0.83%, leading to a total return of 1.85%.<BR><BR>For the 2-year period, the price return was 43.8%, the dividend return was 2.56%, which resulted in a total return of 46.36%.<BR><BR>During the 3-year period, the price return was 56.49%, the dividend return was 3.90%, culminating in a total return of 60.39%.<BR><BR>In the 4-year period, the price return was 53.99%, the dividend return was 4.83%, yielding a total return of 58.82%.<BR><BR>Over the last 5 years, the price return was 103.29%, the dividend return was 7.62%, resulting in a total return of 110.91%.<BR><BR>Overall, Alkem Laboratories Ltd has declared a significant dividend, which reflects positively on the company's commitment to returning value to shareholders. The total returns over various periods show a mix of performance, with particularly strong returns over the longer term.

Who are the peers of the Alkem Lab?

Alkem Lab's peers include Zydus Lifesci., Lupin, Abbott India, Aurobindo Pharma, Glenmark Pharma, Glaxosmi. Pharma, Biocon, Laurus Labs, Cohance Life, and Ipca Labs. In terms of management risk, growth, and capital structure, they vary from excellent to average, with Laurus Labs showing the highest 1-year return at 76.44% and Zydus Lifesci. the lowest at -18.37%.

Peers: The peers of Alkem Lab are Zydus Lifesci., Lupin, Abbott India, Aurobindo Pharma, Glenmark Pharma, Glaxosmi. Pharma, Biocon, Laurus Labs, Cohance Life, and Ipca Labs.<BR><BR>Quality Snapshot: Excellent management risk is observed at Abbott India and Glaxosmi. Pharma, while Good management risk is found at Zydus Lifesci., Aurobindo Pharma, Laurus Labs, Alkem Lab, and Cohance Life, and Average management risk is noted at Lupin, Glenmark Pharma, and Biocon. In terms of Growth, Excellent growth is seen at Zydus Lifesci. and Lupin, while Average growth is noted at Laurus Labs and Biocon, and Below Average growth is observed at Aurobindo Pharma, Glenmark Pharma, Alkem Lab, Glaxosmi. Pharma, and Cohance Life. For Capital Structure, Excellent capital structure is found at Zydus Lifesci., Abbott India, Aurobindo Pharma, Alkem Lab, Glaxosmi. Pharma, Cohance Life, and Ipca Labs, while Good capital structure is noted at Lupin and Glenmark Pharma, and Average capital structure is seen at Laurus Labs and Biocon.<BR><BR>Return Snapshot: The peer with the highest 1-year return is Laurus Labs at 76.44%, while the peer with the lowest is Zydus Lifesci. at -18.37%. Alkem Lab's 1-year return is -5.54%, which is higher than Zydus Lifesci. but lower than Laurus Labs. Additionally, the peers with negative six-month returns include Zydus Lifesci., Aurobindo Pharma, and Glenmark Pharma.

Who are in the management team of Alkem Lab?

As of March 2023, the management team of Alkem Lab includes Basudeo N Singh (Executive Chairman), Sandeep Singh (Managing Director), and several Executive and Non-Executive Directors, along with the Company Secretary, Manish Narang, who collectively guide the company's governance and strategy.

As of March 2023, the management team of Alkem Lab includes the following individuals:<BR><BR>1. Basudeo N Singh - Executive Chairman<BR>2. Sandeep Singh - Managing Director<BR>3. Mritunjay Kumar Singh - Executive Director<BR>4. Sarvesh Singh - Executive Director<BR>5. Madhurima Singh - Executive Director<BR>6. Srinivas Singh - Executive Director<BR>7. A K Purwar - Non-Executive & Independent Director<BR>8. Sangeeta Kapiljit Singh - Non-Executive & Independent Director<BR>9. Sudha Ravi - Non-Executive & Independent Director<BR>10. Dheeraj Sharma - Non-Executive & Independent Director<BR>11. Narendra Aneja - Non-Executive & Independent Director<BR>12. Sujjain Talwar - Independent Director<BR>13. Manish Narang - Company Secretary & Compliance Officer<BR><BR>This diverse team plays a crucial role in the governance and strategic direction of the company.

What does Alkem Lab do?

Alkem Laboratories Ltd is a prominent Indian pharmaceutical company founded in 1973, specializing in the development and sale of pharmaceutical and nutraceutical products. As of March 2025, it reported net sales of ₹31,438 Cr and a net profit of ₹3,059 Cr, with a market capitalization of ₹59,352 Cr.

Overview:<BR>Alkem Laboratories Ltd is a leading Indian pharmaceutical company engaged in the development, manufacture, and sale of pharmaceutical and nutraceutical products, operating within the Pharmaceuticals & Biotechnology industry and categorized as a Large Cap company.<BR><BR>History:<BR>Alkem Laboratories Ltd was incorporated in the year 1973. The latest quarterly results reported are for March 2025, showcasing the company's ongoing operations in the pharmaceutical sector.<BR><BR>Financial Snapshot:<BR>Most recent Net Sales: 31,438 Cr (Quarterly Results - Mar 2025) <BR>Most recent Net Profit: 3,059 Cr (Quarterly Results - Mar 2025) <BR>Market-cap value: INR 59,352 Cr (Large Cap)<BR><BR>Key Metrics:<BR>P/E: 28.00 <BR>Industry P/E: 37 <BR>Dividend Yield: 0.85% <BR>Debt-Equity: -0.09 <BR>Return on Equity: 18.07% <BR>Price to Book: 4.92 <BR><BR>Contact Details:<BR>Address: Alkem House Senapati Bapat Marg, Lower Parel Mumbai Maharashtra : 400013 <BR>Tel: 91-22-39829999 <BR>Email: investors@alkem.com <BR>Website: http://www.alkemlabs.com

When is the next results date for Alkem Lab?

Alkem Lab will announce its results on 12 August 2025.

Alkem Lab will declare its results on 12 August 2025.

Are Alkem Lab latest results good or bad?

Alkem Laboratories' latest results show strong profitability and sales growth, with a 24.55% increase in Profit Before Tax and an 11.19% rise in net sales. However, declining cash reserves and a slowdown in net profit growth have led to cautious sentiment among analysts, resulting in a 'Sell' recommendation from MarketsMOJO.

Alkem Laboratories' latest results present a mixed picture. On one hand, the company has demonstrated a positive trend in profitability, with a Profit Before Tax (PBT) of Rs 621.59 crore, marking a year-on-year growth of 24.55%. Additionally, net sales have increased by 11.19% compared to the same quarter last year, which is a positive sign for revenue growth.<BR><BR>However, there are concerns regarding the company's financial health. The cash and cash equivalents have fallen to their lowest level in the last three half-yearly periods, now standing at Rs 1,563.08 crore. This decline raises questions about the company's short-term liquidity and financial flexibility. Furthermore, the consolidated net profit growth has slowed to 21.85%, down from a much higher growth rate of 90.13% in the previous year.<BR><BR>The stock has also received a 'Sell' recommendation from MarketsMOJO, indicating cautious sentiment among analysts regarding its current financial standing. Overall, while there are positive aspects in terms of profitability and sales growth, the liquidity issues and analyst sentiment suggest that the results are viewed with caution.

Is Alkem Lab overvalued or undervalued?

As of November 13, 2025, Alkem Lab is fairly valued with a PE ratio of 30.06 and solid financial metrics, despite recent stock performance lagging behind the Sensex.

As of 13 November 2025, the valuation grade for Alkem Lab has moved from expensive to fair. The company is currently fairly valued, with a PE ratio of 30.06, a Price to Book Value of 5.70, and an EV to EBITDA ratio of 25.45. In comparison to its peers, Sun Pharma has a higher PE ratio of 36.15 and an EV to EBITDA of 23.85, while Cipla is more attractively valued with a PE of 22.65 and an EV to EBITDA of 16.03.<BR><BR>Alkem Lab's financial metrics indicate a solid performance, with a ROCE of 19.77% and a ROE of 18.07%. Despite recent stock performance lagging behind the Sensex over one year (2.53% vs. 8.74%), the company's strong ratios suggest it is positioned well within the pharmaceuticals sector. Overall, Alkem Lab appears to be fairly valued in the current market context.

How has been the historical performance of Alkem Lab?

Alkem Lab has shown consistent growth in net sales and profits, with net sales increasing from 8,344.36 Cr in March 2020 to 12,964.52 Cr in March 2025, and profit after tax rising from 1,149.31 Cr to 2,216.00 Cr during the same period, indicating strong financial performance.

Answer:<BR>The historical performance of Alkem Lab shows a consistent growth trend in net sales and profits over the years, culminating in significant figures for the fiscal year ending March 2025.<BR><BR>Breakdown:<BR>Alkem Lab's net sales increased from 8,344.36 Cr in March 2020 to 12,964.52 Cr in March 2025, reflecting a steady upward trajectory. The total operating income followed a similar pattern, rising from 8,344.36 Cr in March 2020 to 12,964.52 Cr in March 2025. The company's operating profit (PBDIT) also saw growth, reaching 3,005.89 Cr in March 2025, up from 1,577.61 Cr in March 2020. Profit before tax increased from 1,259.79 Cr in March 2020 to 2,527.03 Cr in March 2025, while profit after tax rose from 1,149.31 Cr to 2,216.00 Cr over the same period. The earnings per share (EPS) improved significantly from 94.28 in March 2020 to 181.14 in March 2025. On the balance sheet, total assets grew from 9,012.97 Cr in March 2020 to 15,952.85 Cr in March 2025, and total liabilities increased from 9,012.97 Cr to 15,952.85 Cr during the same timeframe. Cash flow from operating activities also showed an upward trend, reaching 1,912.00 Cr in March 2025, although the net cash outflow was recorded at -186.00 Cr. Overall, Alkem Lab has demonstrated robust growth in sales, profits, and assets over the years, indicating a strong financial performance.

Is Alkem Lab technically bullish or bearish?

As of December 1, 2025, Alkem Lab's technical trend is mildly bullish, supported by bullish weekly MACD and Bollinger Bands, despite mixed signals from monthly indicators.

As of 1 December 2025, the technical trend for Alkem Lab has changed from bullish to mildly bullish. The weekly MACD remains bullish, while the monthly MACD is mildly bearish, indicating mixed signals across time frames. The Bollinger Bands are mildly bullish on both weekly and monthly charts, supporting a positive outlook. Daily moving averages are bullish, reinforcing the mildly bullish stance. However, the KST shows a bullish weekly trend but is mildly bearish monthly, and Dow Theory indicates a mildly bearish weekly trend with no clear monthly trend. Overall, the current technical stance is mildly bullish, driven primarily by the weekly MACD and Bollinger Bands, despite some bearish signals in the monthly indicators.

Should I buy, sell or hold Alkem Lab?

Which are the latest news on Alkem Lab?

Why is Alkem Laboratories Ltd falling/rising?

As of 28-Jan, Alkem Laboratories Ltd's stock price is 5,722.35, down 0.56%, but it has shown positive performance over various time frames, including a 3.95% year-to-date gain. Despite today's decline, the stock has strong fundamentals and outperformed the Sensex over the past year.

As of 28-Jan, Alkem Laboratories Ltd's stock price is currently at 5,722.35, reflecting a decrease of 32.1 points or 0.56%. Despite this recent decline, the stock has shown positive performance over various time frames. For instance, over the past week, it has risen by 1.14%, and over the past month, it has increased by 3.38%. Year-to-date, the stock has gained 3.95%, and over the past year, it has outperformed the Sensex with a return of 16.24% compared to the index's 8.49%.<BR><BR>The stock is currently 3.68% away from its 52-week high of Rs 5,933, indicating that it is close to its peak value. However, today's performance has underperformed its sector by 1.04%, which may contribute to the current price drop. Additionally, there has been a notable decline in investor participation, with delivery volume falling by 20.5% compared to the 5-day average, suggesting reduced trading interest.<BR><BR>On a positive note, Alkem Laboratories Ltd maintains high management efficiency with a return on equity (ROE) of 16.90% and a low debt-to-equity ratio, which supports its fair valuation. The stock has high institutional holdings at 31.51%, indicating confidence from larger investors. Overall, while the stock is experiencing a slight decline today, its long-term performance remains strong, outperforming benchmarks and demonstrating solid fundamentals.